A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

Inclusion Criteria: 1. Be able to understand and willing to sign the Informed Consent Form; 2. Male or female aged 18\~75 years (included); 3. Patients with pathologically confirmed advanced malignant solid tumors or lymphomas; 4. Failed or unsuitable for standard treatment, received at least one line of systemic treatment; 5. Eastern Cooperative Oncology Group (ECOG) physical fitness score: 0\~1; 6. Expected survival period ≥ 12 weeks; 7. At least one measurable lesion according to criteria RECIST v1.1 or Lugano 2014; Exclusion Criteria: 1. Patients with known hypersensitivity to the components of JS019; 2. Patients who have received the treatment with anti-CD39 antibodies or inhibitors; 3. Patients who participated in other clinical studies within 4 weeks prior to the first administration of JS019, except patients are in the follow-up period of observational (non-interventional) clinical study or interventional study; 4. Patients who have received major surgery within 4 weeks before the first dose or expected to undergo major surgery during the study (as judged by the investigator) or are in the recovery period from surgery; 5. Patients who have received anti-tumor therapy, such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or biological therapy, within 4 weeks or 5 half-lives of the therapy (whichever is shorter) prior to the first dose of JS019. Patients who have received traditional Chinese medicine or Chinese patent medicine preparations with anti-tumor indications within 2 weeks before the first dose of JS019. Can accept hormone therapy for non-tumor-related diseases (such as insulin therapy for diabetes and hormone replacement therapy, etc.); 6. Patients who have discontinued immunotherapy due to immune-related AEs. 7. Patients who have used immunosuppressive drugs within 4 weeks prior to the first dose of JS019, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids ≤10 mg/day prednisone or equivalent.